Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) Director Steve E. Krognes sold 2,253 shares of Denali Therapeutics stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $33.22, for a total value of $74,844.66. Following the completion of the transaction, the director now owns 149,468 shares of the company’s stock, valued at approximately $4,965,326.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Denali Therapeutics Trading Up 0.1 %
DNLI traded up $0.03 during trading hours on Tuesday, reaching $32.02. The company’s stock had a trading volume of 491,102 shares, compared to its average volume of 595,974. Denali Therapeutics Inc. has a fifty-two week low of $20.24 and a fifty-two week high of $56.80. The business’s 50-day moving average is $32.72 and its 200-day moving average is $30.39.
Denali Therapeutics (NASDAQ:DNLI – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.07. Denali Therapeutics had a negative return on equity of 30.06% and a negative net margin of 252.50%. The firm had revenue of $52.50 million for the quarter, compared to analysts’ expectations of $44.66 million. During the same period in the prior year, the firm posted ($0.50) earnings per share. The firm’s quarterly revenue was up 129.3% on a year-over-year basis. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.68 EPS for the current year.
Institutional Inflows and Outflows
Ad RJO Futures
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
A number of large investors have recently added to or reduced their stakes in DNLI. State Street Corp lifted its holdings in Denali Therapeutics by 26.4% in the first quarter. State Street Corp now owns 3,826,792 shares of the company’s stock valued at $123,108,000 after acquiring an additional 799,221 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Denali Therapeutics by 72.6% during the first quarter. Bank of New York Mellon Corp now owns 1,609,217 shares of the company’s stock worth $51,769,000 after purchasing an additional 676,625 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Denali Therapeutics during the second quarter worth $18,992,000. Woodline Partners LP increased its position in shares of Denali Therapeutics by 389.3% during the first quarter. Woodline Partners LP now owns 256,678 shares of the company’s stock worth $8,257,000 after acquiring an additional 204,224 shares during the period. Finally, American Century Companies Inc. increased its position in shares of Denali Therapeutics by 53.7% during the fourth quarter. American Century Companies Inc. now owns 536,282 shares of the company’s stock worth $23,918,000 after acquiring an additional 187,295 shares during the period. 72.32% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on DNLI shares. Wedbush cut their price target on Denali Therapeutics from $62.00 to $48.00 in a research note on Friday, May 6th. Berenberg Bank started coverage on Denali Therapeutics in a research note on Thursday, June 23rd. They set a “buy” rating and a $39.00 price objective for the company. Finally, The Goldman Sachs Group cut their price objective on Denali Therapeutics from $99.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $76.29.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Denali Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Denali Therapeutics wasn’t on the list.
While Denali Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 2,253 Shares of